Touchlight’s cell-free DNA platform offers a fundamentally different approach to DNA manufacturing—enabling the rapid, scalable, and high-quality production of enzymatically produced DNA for advanced therapies.

At the core of this platform are three complementary technologies: dbDNA™, mbDNA™ + Custom Circles, and z- dbDNA™—each designed to address specific needs across the development lifecycle. Together, they provide flexible solutions for applications ranging from early discovery through to clinical and commercial manufacturing.

By eliminating the need for bacterial fermentation, Touchlight’s technologies offer a cleaner, more controlled alternative to plasmid DNA. This cell-free approach reduces complexity, accelerates timelines, and supports the growing demands of gene therapy, gene editing, and other nucleic acid-based medicines.

Whether enabling high-quality templates for AAV production, supporting next-generation gene editing strategies, or unlocking new construct designs, Touchlight’s platform is designed to deliver speed, scalability, and reliability where it matters most.

Download this overview to explore how Touchlight’s cell-free DNA platform is helping advance genetic medicine development with greater efficiency and control.